October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Hagop Kantarjian: Low-dose azacitidine plus venetoclax – in patients with AML unable to complete standard consolidation strategies
Apr 5, 2024, 08:22

Hagop Kantarjian: Low-dose azacitidine plus venetoclax – in patients with AML unable to complete standard consolidation strategies

Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Low-dose azacitidine plus venetoclax maintains remissions with manageable side effects in patients with AML unable to complete standard consolidation strategies (2-year modified RFS and OS of 56% and 72%).”

Hagop Kantarjian: Low-dose azacitidine plus venetoclax - in patients with AML unable to complete standard consolidation strategies

Proceed to the article.
Source: Hagop Kantarjian/X